PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
PROVECTUS BIOPHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026
- Market cap
- $20.55M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 420M shares
Institutional holders
4
0 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jeffrey Allen Morris | 61,100,610 | 11.30% | 13G (passive) | Aug 12, 2024 |
| Pershing Edward | 52,441,275 | 11.61% | 13D (active) amendment | Jun 30, 2026 |
| Dominic Rodrigues | 25,220,549 | 5.67% | 13D (active) | Dec 2, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PVCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Home Federal Bank Of Tennessee | 100,000 | 0.02% | $6.90K | – | 0.00% |
| Atlas Wealth LLC | 19,620 | 0.00% | $1.36K | – | 0.00% |
| Financial Symmetry Inc | 10,191 | 0.00% | $707 | – | 0.00% |
| Huntington National Bank | 1 | 0.00% | $0 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q1 2026 | 6 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2025 | 5 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q3 2025 | 7 | 0M | 0.1% | 0 / 1 | 0 / 0 | 0M | 0M |
| Q2 2025 | 7 | 0M | 0.1% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q1 2025 | 7 | 0M | 0.1% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2024 | 6 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2024 | 7 | 0M | 0.1% | 0 / 0 | 2 / 0 | 0M | 0M |
| Q2 2024 | 7 | 0M | 0.1% | 1 / 1 | 0 / 0 | 0M | 0M |
| Q1 2024 | 6 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2023 | 7 | 0M | 0.1% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q3 2023 | 6 | 0M | 0.1% | 0 / 0 | 0 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Edward Pershing | CEO, Director, 10% owner | 3,532,980 | 0.84% | Sep 18, 2026 |
| Dominic Rodrigues | PRESIDENT, Director | 1,201,214 | 0.29% | Jun 30, 2026 |
| Eric Wachter Phd | CTO | 6,649,298 | 1.58% | Dec 4, 2024 |
| Heather Raines | CFO | 1,213,153 | 0.29% | Dec 4, 2024 |
| John Lacey III | Director | 200,450 | 0.05% | Jun 30, 2026 |
| Webster Bailey | Director | 145,528 | 0.03% | Jun 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey Allen Morris 10% owner | Aug 12, 2024 | Conversion | +264,314 | $2.86 | $755.94K | 4,260,061 |
| Jeffrey Allen Morris 10% owner | May 8, 2023 | Conversion | +188,757 | $2.86 | $539.85K | 3,995,747 |
| Heather Raines CFO | Nov 10, 2020 | Award | +50,000 | – | – | 1,213,153 |
| Bruce Horowitz Chief Operating Officer, Director | Nov 10, 2020 | Award | +800,000 | – | – | 2,227,243 |
| John Lacey III Director | Nov 10, 2020 | Award | +100,000 | – | – | 200,000 |
| Heather Raines Chief Financial Officer | Mar 25, 2019 | Award | +50,000 | – | – | 1,163,153 |
| John R. Glass See Remarks | Dec 14, 2017 | Buy | +115,900 | $0.05 | $5.80K | 200,000 |
| John R. Glass See Remarks | Dec 14, 2017 | Buy | +84,100 | $0.05 | $4.21K | 84,100 |
| Peter R. Culpepper Interim CEO, CFO, COO | Mar 29, 2016 | Exercise | +133,333 | $1.00 | $133.33K | 1,384,496 |
| Peter R. Culpepper Interim CEO, CFO, COO | Mar 29, 2016 | Exercise | +27,333 | $1.00 | $27.33K | 1,411,829 |
| Peter R. Culpepper Interim CEO, CFO, COO | Mar 29, 2016 | Exercise | +106,000 | $1.00 | $106.00K | 296,503 |
| Eric Wachter Phd Chief Technology Officer, Director | Mar 29, 2016 | Exercise | +106,000 | $1.00 | $106.00K | 930,248 |
| Eric Wachter Phd Chief Technology Officer, Director | Mar 29, 2016 | Exercise | +200,947 | $1.00 | $200.95K | 5,714,183 |
| Jan Koe Director | Mar 29, 2016 | Exercise | +100,000 | $1.25 | $125.00K | 786,300 |
| Jan Koe Director | Mar 29, 2016 | Exercise | +100,000 | $1.25 | $125.00K | 686,300 |
| Eric Wachter Phd Chief Technology Officer | Dec 21, 2015 | Option exercise | +120,000 | $1.02 | $122.40K | 5,513,236 |
| Peter R. Culpepper CFO & COO | Dec 9, 2015 | Option exercise | +138,831 | $0.94 | $130.50K | 1,251,163 |
| Peter R. Culpepper CFO & COO | Dec 9, 2015 | Option exercise | +6,383 | $0.94 | $6.00K | 190,503 |
| Eric Wachter Phd Chief Technology Officer | Jan 24, 2015 | Option exercise | +185,000 | $1.02 | $188.70K | 824,248 |
| Timothy Scott Phd President, Director | Jan 7, 2015 | Option exercise | +76,764 | $0.64 | $49.13K | 503,125 |
| Peter R. Culpepper CFO & COO | Jan 7, 2015 | Option exercise | +33,334 | $0.75 | $25.00K | 154,334 |
| Peter R. Culpepper CFO & COO | Jan 7, 2015 | Option exercise | +29,786 | $0.94 | $28.00K | 184,120 |
| Timothy Scott Phd President, Director | Dec 30, 2014 | Option exercise | +126,361 | $0.64 | $80.87K | 426,361 |
| Timothy Scott Phd President, Director | Oct 29, 2014 | Option exercise | +96,875 | $0.64 | $62.00K | 1,521,845 |
| Peter R. Culpepper CFO & COO | Jun 28, 2014 | Option exercise | +100,000 | $1.25 | $125.00K | 1,112,332 |
| Timothy Scott Phd President | May 19, 2014 | Option exercise | +25,000 | $0.95 | $23.75K | 1,424,970 |
| Timothy Scott Phd President | May 19, 2014 | Option exercise | −25,000 | $0.95 | $23.75K | 1,424,970 |
| Eric Wachter Phd Chief Technology Officer | Mar 20, 2014 | Option exercise | +25,000 | $0.95 | $23.75K | 5,418,236 |
| Eric Wachter Phd Chief Technology Officer | Mar 20, 2014 | Option exercise | +600,000 | $0.93 | $558.00K | 6,032,484 |
| Eric Wachter Phd Chief Technology Officer | Mar 20, 2014 | Option exercise | +14,248 | $0.75 | $10.69K | 5,432,484 |
| Timothy Scott Phd President | Feb 26, 2014 | Option exercise | +300,000 | $1.10 | $330.00K | 300,000 |
| Peter R. Culpepper CFO & COO | Feb 26, 2014 | Option exercise | +68,624 | $1.10 | $75.49K | 1,012,332 |
| Peter R. Culpepper CFO & COO | Feb 26, 2014 | Option exercise | +121,000 | $1.10 | $133.10K | 121,000 |
| Jan Koe Director | Sep 20, 2013 | Buy | +100,000 | – | – | 586,300 |
| H. Craig Dees Chief Executive Officer, Director | May 29, 2013 | Option exercise | +18,750 | $0.32 | $6.00K | 1,472,859 |
| H. Craig Dees Chief Executive Officer, Director | May 29, 2013 | Option exercise | +25,000 | $0.60 | $15.00K | 1,497,859 |
| Peter R. Culpepper CFO, COO | Dec 3, 2012 | Buy | +133,333 | – | – | 943,708 |
| Peter R. Culpepper CFO, COO | Nov 16, 2012 | Buy | +133,333 | – | – | 810,375 |
| Eric Wachter Phd Chief Technology Officer | Nov 16, 2012 | Buy | +666,666 | – | – | 5,393,236 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Dec 5, 2011 | Option exercise | +100,000 | $0.75 | $75.00K | 4,726,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Dec 1, 2011 | Option exercise | +100,000 | $0.93 | $93.00K | 4,626,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Nov 23, 2011 | Option exercise | +100,000 | $0.93 | $93.00K | 4,526,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Oct 19, 2011 | Option exercise | +100,000 | $0.93 | $93.00K | 4,426,570 |
| Timothy Scott Phd President, Director | Oct 6, 2011 | Option exercise | +25,000 | $0.60 | $15.00K | 1,399,970 |
| Timothy Scott Phd President, Director | Oct 6, 2011 | Option exercise | +75,000 | $0.32 | $24.00K | 1,374,970 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Sep 7, 2011 | Option exercise | +100,000 | $0.93 | $93.00K | 4,326,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Jul 29, 2011 | Option exercise | +100,000 | $1.00 | $100.00K | 4,226,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | May 3, 2011 | Option exercise | +100,000 | $1.00 | $100.00K | 4,126,570 |
| Peter R. Culpepper Chief Financial Officer | May 3, 2011 | Option exercise | +133,333 | $0.75 | $100.00K | 677,042 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Apr 20, 2011 | Option exercise | +100,000 | $1.00 | $100.00K | 4,026,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Apr 12, 2011 | Option exercise | +150,000 | $1.00 | $150.00K | 3,926,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Feb 7, 2011 | Option exercise | +8,333 | $0.75 | $6.25K | 3,776,570 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Feb 3, 2011 | Option exercise | +125,000 | $0.75 | $93.75K | 3,768,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Dec 29, 2010 | Option exercise | +400,000 | $1.00 | $400.00K | 3,643,237 |
| Peter R. Culpepper Chief Financial Officer | Dec 29, 2010 | Option exercise | +133,333 | $0.75 | $100.00K | 543,709 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Nov 19, 2010 | Option exercise | +100,000 | $1.00 | $100.00K | 3,243,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Sep 7, 2010 | Option exercise | +100,000 | $1.00 | $100.00K | 3,143,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Jul 9, 2010 | Option exercise | +75,000 | $1.10 | $82.50K | 3,043,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Apr 28, 2010 | Option exercise | +52,419 | $0.75 | $39.31K | 2,968,237 |
| Eric Wachter Phd Vice President Pharmaceuticals, Director | Apr 28, 2010 | Option exercise | +105,469 | $0.64 | $67.50K | 2,915,818 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.